Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention
A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of…